- Case report
- Open Access
Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature
BMC Infectious Diseases volume 14, Article number: 514 (2014)
Prolonged asymptomatic carriage of vancomycin-resistant enterococci (VRE) in the gastrointestinal tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings.
We report a regimen for decolonization of gastrointestinal carriage of VRE by a combination of environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any remaining VRE, and subsequent oral Lactobacillus rhamnosus GG to maintain the colonization resistance in four patients, including two patients with end-stage liver cirrhosis, one patient with complication post liver transplant, and one patient with complicated infective endocarditis. All patients had clearance of VRE immediately after decolonization, and 3 of them remained VRE-free for 23 to 137 days of hospitalization, despite subsequent use of intravenous broad-spectrum antibiotics without anti-VRE activity.
This strategy should be further studied in settings of low VRE endemicity with limited isolation facilities.
Vancomycin-resistant enterococci (VRE) has been endemic in many parts of the word. Prolonged asymptomatic carriage of VRE in the gastrointestinal tract and the lack of effective decolonization regimen perpetuate the endemicity of VRE in the healthcare settings . In Hong Kong, an increasing number of sporadic cases of VRE are observed, with a prevalence of 0.32% of admission episodes by active surveillance culture . We adopted a proactive infection measures by the implementation of active surveillance culture, extensive contact tracing, isolation of VRE-positive patients and environmental disinfection to control nosocomial transmission of VRE [2–4]. However, the limited availability of single rooms fails to match with the increasing number of patients colonized with VRE in recent years. Therefore, an effective regimen for VRE decolonization is necessary in resource-limited areas like Hong Kong. Here, we report a protocol of VRE decolonization in four patients, including two patients with end-stage liver cirrhosis awaiting liver transplantation, one patient with a complicated post-liver transplant recovery, and one patient with complicated infective endocarditis. Decolonization of VRE is crucial in liver transplant candidates as VRE colonization is associated with an increased risk of infection and death among liver transplant recipients . In contrast to the previous attempt of VRE decolonization using only antimicrobial agents or probiotics, we include the use of polyethylene glycol for bowel preparation to wash-out the fecal bacterial population prior to the administration of oral linezolid and daptomycin. Lactobacillus rhamnosus GG is then given to maintain the colonization resistance after antimicrobial decolonization. Our aim of VRE decolonization was to reduce the risk of subsequent invasive VRE infection among the high-risk patients, and to limit the risk of nosocomial transmission of VRE in our locality.
Decolonization of gastrointestinal carriage of VRE
Case 1: A 59-year-old man was referred to the Liver Transplant Unit of Queen Mary Hospital, a university-affiliated hospital with 1,600 bed, for consideration of cadaveric liver transplantation due to chronic hepatitis B-related end-stage cirrhosis on 14 September 2013. Queen Mary Hospital is the only liver transplant center in Hong Kong, with approximately 80 patients undergoing liver transplantation per year. Upon admission, rectal swab with visible stool content was collected for the detection of multidrug-resistant organisms including VRE in accordance to the hospital infection control policy. Briefly, patients with history of hospitalization or receiving surgical operation outside Hong Kong within the past 12 months before admission or patients with history of admissions to other local hospitals within the past 3 months were included in the active surveillance [2, 4, 6]. The patient was confirmed to be positive for vancomycin-resistant Enterococcus faecium which was resistant to ampicillin, chloramphenicol, nitrofurantoin, levofloxacin, minocycline, rifampicin, tetracycline, fosfomycin, high-level gentamicin, and high-level streptomycin. The minimal inhibitory concentration (MIC) of vancomycin was >256 μg/ml. VanA gene was detected by polymerase chain reaction (PCR). The MIC of linezolid and daptomycin was 1.5 μg/ml and 3.0 μg/ml respectively, while the MIC breakpoint of linezolid and daptomycin was ≤ 2 μg/ml and ≤ 4 μg/ml for enterococcus species respectively with reference to Clinical and Laboratory Standards Institute. Multilocus sequence typing (MLST) demonstrated that the strain was ST761 (profile 70-1-1-1-12-1-1), which is a member of the pandemic clonal complex 17 lineage. The patient was isolated in a single room with strict contact precautions since day 2 of hospitalization. Healthcare workers wore gloves and gowns during patient care practice. Alcohol-based hand rub was provided in the isolation room for hand hygiene. Dedicated medical items such as stethoscope, thermometer, and blood pressure cuff were available and solely used on this patient. Decolonization of VRE was performed between day 11 and 15 of hospitalization according to our protocol (Table 1). The bacterial load of VRE in rectal swabs with visible stool content was monitored daily. The VRE counts decreased from >2×105 colony forming units per gram (cfu/g) of stool (baseline on day 11) to 3.4×104 cfu/g of stool on day 12 and undetectable (<200 cfu/g) on day 13. Despite the administration of broad-spectrum antibiotics after successful decolonization, the serial rectal swabs remained negative for VRE in vancomycin and clindamycin containing enterococcal enrichment broth culture (Figure 1). ABO blood group matched-cadaveric liver graft became available on day 30 of hospitalization and transplantation was performed under coverage with intravenous linezolid 600 mg 30 minutes before surgical incision, and one dose postoperatively. The operation lasted for 11 hours without immediate complications. Patient was managed in the adult intensive care unit during the postoperative period and transferred to the liver transplant ward on day 32 of hospitalization (post-operative day 2). Serial rectal swabs were collected on day 1, 3, 4, 5, 7, 10, 12, 14, and 17 after liver transplantation, thereafter twice weekly until day 66, and weekly until day 107 after liver transplantation (day 137 of hospitalization) (Figure 1). No growth of VRE was detected in broth enrichment culture.Case 2: A 56-year-old man had living-donor liver transplantation for early stage of moderately differentiated hepatocellular carcinoma on 31 July 2012. He developed recurrent ascites as a result of portal vein and hepatic vein stenosis 6 months post-transplant requiring multiple episodes of hospitalization. On 26 February 2014, he was detected to have gastrointestinal colonization of VRE and was subjected to VRE decolonization after 13 days of hospitalization (Figure 2). However, patient had poor tolerance to oral ingestion of polyethylene glycol for bowel preparation due to refractory ascites. Since the procedure of decolonization was started, it was continued despite insufficient bowel preparation. Patient had transient suppression of VRE between day 14 and 19 and VRE relapsed on day 27 of hospitalization. The decolonization regimen was not successful in this case with inadequate bowel preparation.Case 3: A 44-year-old man was transferred from a regional hospital to the Liver Transplant Unit of Queen Mary Hospital for consideration of cadaveric liver transplantation due to hepatitis B-related hepatic failure on 15 March 2014. He was found to have gastrointestinal carriage of VRE upon admission screening. While waiting for a potential liver graft, VRE decolonization was initiated on day 5 of hospitalization. He remained VRE negative on serial monitoring till day 62 of hospitalization despite intermittent use of antibiotics (Figure 3).Case 4: A 71-year-old-lady was transferred from a regional hospital to the Cardiothoracic Surgical Unit, Queen Mary Hospital, for consideration of surgical intervention for viridans streptococci-related infective endocarditis complicated with cardiac failure. She had history of chronic rheumatic heart disease with mitral stenosis, mitral regurgitation, aortic regurgitation, and tricuspid regurgitation. She was noted to have gastrointestinal carriage of VRE upon admission screening, and was put on VRE decolonization as per protocol on day 10 of hospitalization. Serial rectal swabs culture remained VRE negative (broth enrichment culture) till day 23 of hospitalization (Figure 4). However, patient developed respiratory distress, metabolic acidosis, hypotension, oliguric renal impairment, and radiological appearance of dilated bowel loops suggestive of mesenteric ischemia on day 25. Urgent exploratory laparotomy revealed the presence of 300 ml foul-smelling, blood-stained peritoneal fluid with gangrenous change of bowel from duodenojejunal flexure to mid-sigmoid colon. Despite empirical use of meropenem and daptomycin, inotropic and ventilator support, patient succumbed on day 26 of hospitalization. No VRE could be detected in all her clinical specimens or serial rectal swabs after decolonization.
For VRE screening, stool or rectal swabs with visible fecal components were inoculated onto chromogenic agar (chromID VRE, bioMerieux, France) and incubated aerobically at 35°C for 48 hours for identification by Vitek 2 automated identification system (bioMerieux, France) as previously described . The Kirby-Bauer disk diffusion method and E-test (AB Biodisk, Solna, Sweden) were used to determine the antimicrobial susceptibility of the enterococci. Isolates with potential vancomycin resistance were proceeded to vanA gene PCR and MLST as previously described . For VRE bacterial load quantitation, around 1 g of fecal sample was suspended into 2 ml normal saline and serially diluted suspensions were plated onto chromogenic agar. In addition, broth enrichment was performed by inoculating another 10 μl aliquot of the fecal suspension into the vancomycin containing brain-heart-infusion broth. The broth was incubated at 37°C overnight and further subcultured onto chromogenic agar in 35°C aerobic incubation for 48 hours. The lower detection limit of this method is 200 cfu/g.
Decolonization of VRE poses a great challenge for clinical microbiologists and infection control professionals. It is difficult to suppress the fecal burden of enterococci, ranging from 1–10 million cfu/g of stool, within the gastrointestinal tract by sole use of antimicrobial agents that are only bacteriostatic. We aim to overcome the problem of significant enterococci burden by mechanical removal of fecal load before the administration of high concentration of topical antimicrobial agents. Therefore, in addition to systemic and topical antibiotics, we adopt a protocol for bowel wash-out commonly used prior to colonoscopy to remove the majority of the fecal bacterial burden, and combined it with adjunctive infection control measures and probiotic. To our knowledge, the use of polyethylene glycol for bowel preparation in the aim to eliminate fecal bacterial population has not been attempted in previous eradication protocols for VRE or other multiple drug resistant bacteria. We have successfully eradicated VRE carriage in a high-risk patient with end-stage cirrhosis before cadaveric liver transplantation. This patient was chosen as the first case in our pilot study because decolonization of VRE is crucial in liver transplant candidates. In one study, it was found that liver transplant candidates and recipients with VRE colonization had an increased risk of VRE infection (adjusted odd ratio 3.61, 95% CI 2.01-6.47) and of death (adjusted odd ratio 2.12, 95% CI 1.27-3.54) compared with non-colonized patients .
In the literature, antimicrobial agents with high luminal concentration had been used to decolonize gastrointestinal carriage of VRE in 142 patients (Table 2). Bacitracin-containing regimens given orally or via gastrostomy tube for 10 days to 29 days were most common, and was used in 76 (54%) of 142 patients [7–12]. The results were rather variable, while the overall observed rate of VRE clearance was found to be 43% to 100% in patients treated with bacitracin-containing regimens [7, 9, 11], long term follow up showed that VRE free was only observed in 33% to 53% at 3 weeks post-treatment [8, 10]. In one study using a combination of oral bacitracin and doxycycline as VRE eradication regimen, although quantitation of VRE in stool showed an initial 3-log reduction of VRE count per gram of stool during the 2-week therapy, the VRE count in stool increased to pretreatment levels of 7.8 and 7.4 log10/g at 2–4 and 5–7 weeks post-treatment respectively . In another randomized placebo controlled study to assess the use of 10-day course of zinc bacitracin capsules in enteric eradication of VRE, only 2 (33%) of 6 patients in each group were VRE negative after 3 weeks suggesting that there was no difference in eradication rate of VRE in the zinc bacitracin and the control group . In a later study, combination of oral bacitracin and gentamicin was evaluated. After 3 months of follow up, only 5 (18%) of 28 patients had no VRE isolated from stool cultures. Antimicrobial side effects were a major concern. Of the 45 patients originally enrolled on the treatment arm, 17 (38%) could not tolerate bacitracin and gentamicin because of nausea, vomiting, and diarrhea . Ramoplanin, an orally administered lipoglycodepsipeptide antibiotic that is not absorbed systemically, has in vitro activity against vancomycin-resistant E. faecium and E. faecalis, and has been shown to suppress gastrointestinal colonization of VRE in up to 90% of patients during the course of ramoplanin in a phase II, double-blinded, randomized, multicenter, placebo-controlled study. However, recurrence of VRE colonization was observed in most patients 14 days after treatment [13, 14]. Short courses of novobiocin in combination with tetracycline or doxycycline were also ineffective in eradicating gastrointestinal carriage of VRE .
With reference to the suboptimal VRE eradication outcomes in the literature when antimicrobial treatment was used alone without fecal wash-out, we attempted to reduce the microbial burden of the gastrointestinal tract by performing bowel wash-out prior to antimicrobial treatment. In addition, we used a new combination of a 5-day course of oral linezolid with systemic effect and oral non-absorbable daptomycin with topical effect to maximize the anti-VRE activity in the gastrointestinal tract. Daptomycin oral therapy had previously been given with minimal systemic absorption . Oral absorbable linezolid may help to decrease VRE counts in biliary or urinary system, but even systemic antibiotics may not work if patients have stone or parasitic nidus in the biliary or urinary tract associated with biofilm formation which can be colonized by VRE. Thus organ imaging to exclude these kinds of foci would be important before instituting the decolonization. This regimen successfully reduced the quantitative bacterial count of VRE from 104 - 105 cfu/g of stool to undetectable level within 3 days of decolonization therapy in at least 3 patients (case 1, case 3, and case 4). However, our regimen failed in one patient (case 2) who could not tolerate oral ingestion of polyethylene glycol for bowel preparation due to refractory ascites. We believe that complete fecal wash-out is the key component of our VRE decolonization regimen.
Adjunctive infection control measures are essential to prevent re-acquisition of VRE from patients’ skin and hospital environment during the process of decolonization. Preparation of 4% chlorhexidine gluconate bath and shampoo was used to reduce the cutaneous colonization of VRE as previously described . Thorough environmental disinfection by sodium hypochlorite 1,000 ppm was done twice daily. At the time of bathing, the patient’s clothes, underwear, and bed linens were replaced and sent for hot laundry daily. Probiotic Lactobacillus rhamnosus GG 80 mg daily for repopulating the gram positive anaerobic flora was used after the 5-day course of linezolid and daptomycin to consolidate the effect of decolonization and may improve the colonization resistance against re-colonization by VRE. In fact, use of Lactobacillus rhamnosus GG or Lactobacillus rhamnosus Lcr35 had been attempted to decolonize 49 patients in the literature with variable results (Table 3). A randomized placebo-controlled study using standard dose of Lactobacillus for 3 weeks in children showed that rectal swab was rendered negative for VRE at the end of therapy in 63% of patients using semi-quantitative method without broth enrichment, but the difference in VRE carrier state was no longer significant 1 week after completion of treatment , suggesting that the effect of Lactobacillus alone may be temporary. Furthermore, using probiotic containing Lactobacillus species alone may not be feasible in patient receiving antibiotics . In contrast, with the appropriate use of fecal wash-out, antimicrobial agents, and Lactobacillus rhamnosus GG, our patients appeared to maintain a persistent VRE negative status, tested by broth enrichment culture of fecal samples, despite the use of broad-spectrum antibiotics after the decolonization.
The major limitation in this study is that the experience with our decolonization regimen was restricted to four patients to date. Additionally, there are potential risks and discomfort associated with the use of polyethylene glycol for fecal wash-out. Patients with severe renal impairment may have a risk of fluid retention and electrolyte disturbance. Patients with refractory ascites may not be able to tolerate the volume of polyethylene glycol. Inadequate bowel preparation may subsequently result in failure of VRE decolonization, like case 2 in our series. Further clinical trials should be performed to validate the effectiveness of this regimen and assess the potential development of antimicrobial resistance, as linezolid and daptomycin will be increasingly used in hospitals with rising incidence of infections due to resistant organisms [22, 23]. Stool concentration of oral linezolid and daptomycin can be done to compare against the measured MICs of the VRE isolates. However, we believe that the findings in this study are significant, where high-risk patient (case 1) with critical underlying co-morbidities has remained VRE negative for over 100 days after decolonization, even with subsequent use of broad-spectrum antibiotic therapy. Cost-effective analysis should be conducted in subsequent studies to measure the expenditure in VRE decolonization and medical management of invasive VRE infections. In addition, VRE decolonization on an outpatient basis, such as patient’s own residence, may be explored, especially in resource-poor regions where prolonged hospitalization for the purpose of decolonization may not be feasible.
Our experience revealed that sustained decolonization of gastrointestinal carriage of VRE was possible by a combination of environmental disinfection, patient isolation, bowel preparation to wash-out the fecal bacterial population using polyethylene glycol, a five-day course of oral absorbable linezolid and non-absorbable daptomycin to suppress any remaining VRE, and subsequent oral Lactobacillus rhamnosus GG to maintain the colonization resistance. This strategy should be further studied in settings of low VRE endemicity with limited isolation facilities.
Written informed consent was obtained from the four patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
This study has been approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.
Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, Baquero F, Grundmann H, Bonten MJ: Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis. 2005, 11 (6): 821-828. 10.3201/1106.041204.
Cheng VC, Tai JW, Chen JH, So SY, Ng WC, Hung IF, Leung SS, Wong SC, Chan TC, Chan FH, Ho PL, Yuen KY: Proactive infection control measures to prevent nosocomial transmission of vancomycin-resistant enterococci in Hong Kong. J Formos Med Assoc. 2014, 113 (10): 734-741. 10.1016/j.jfma.2014.04.001.
Cheng VC, Chan JF, Tai JW, Ho YY, Li I, To KK, Ho PL, Yuen KY: Successful control of vancomycin-resistant Enterococcus faecium outbreak in a neurosurgical unit at non-endemic region. Emerg Health Threats J. 2009, 2: e9-
Cheng VC, Tai JW, Ng ML, Chan JF, Wong SC, Li IW, Chung HP, Lo WK, Yuen KY, Ho PL: Extensive contact tracing and screening to control the spread of vancomycin-resistant Enterococcus faecium ST414 in Hong Kong. Chin Med J (Engl). 2012, 125 (19): 3450-3457.
Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, Pegues DA: Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008, 8 (8): 1737-1743. 10.1111/j.1600-6143.2008.02304.x.
Cheng VC, Chan JF, Wong SC, Chen JH, Tai JW, Yan MK, Kwan GS, Tse H, To KK, Ho PL, Yuen KY: Proactive infection control measures to prevent nosocomial transmission of carbapenem-resistant Enterobacteriaceae in a non-endemic area. Chin Med J (Engl). 2013, 126 (23): 4504-4509.
O’Donovan CA, Fan-Havard P, Tecson-Tumang FT, Smith SM, Eng RH: Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis. 1994, 18 (2): 105-109. 10.1016/0732-8893(94)90074-4.
Chia JK, Nakata MM, Park SS, Lewis RP, McKee B: Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1995, 21 (6): 1520-10.1093/clinids/21.6.1520.
Weinstein MR, Dedier H, Brunton J, Campbell I, Conly JM: Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1999, 29 (2): 361-366. 10.1086/520216.
Mondy KE, Shannon W, Mundy LM: Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2001, 33 (4): 473-476. 10.1086/321895.
Brossier F, Lefrancois S, Paute J, Gouot A, Golmard JL, Chaibi P, Pautas E, Berigaud S, Drieux L, Jarlier V, Aubry A: Decolonisation for early control of an outbreak of vancomycin-resistant Enterococcus faecium in a geriatric rehabilitation care facility. J Hosp Infect. 2010, 76 (4): 368-369. 10.1016/j.jhin.2010.06.020.
Hachem R, Raad I: Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 2002, 23 (1): 43-44. 10.1086/501968.
Montecalvo MA: Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J Antimicrob Chemother. 2003, 51 (Suppl 3): iii31-iii35.
Wong MT, Kauffman CA, Standiford HC, Linden P, Fort G, Fuchs HJ, Porter SB, Wenzel RP: Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis. 2001, 33 (9): 1476-1482. 10.1086/322687.
Montecalvo MA, Horowitz H, Wormser GP, Seiter K, Carbonaro CA: Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1995, 39 (3): 794-10.1128/AAC.39.3.794.
Eisenstein BI, Oleson FB, Baltz RH: Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis. 2010, 50 (Suppl 1): S10-S15.
Karki S, Cheng AC: Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review. J Hosp Infect. 2012, 82 (2): 71-84. 10.1016/j.jhin.2012.07.005.
Szachta P, Ignys I, Cichy W: An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011, 45 (10): 872-877. 10.1097/MCG.0b013e318227439f.
de Regt MJ, Willems RJ, Hene RJ, Siersema PD, Verhaar HJ, Hopmans TE, Bonten MJ: Effects of probiotics on acquisition and spread of multiresistant enterococci. Antimicrob Agents Chemother. 2010, 54 (7): 2801-2805. 10.1128/AAC.01765-09.
Manley KJ, Fraenkel MB, Mayall BC, Power DA: Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007, 186 (9): 454-457.
Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O: Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010, 48 (7): 2595-2598. 10.1128/JCM.00473-10.
Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, Broyles J, Moore KL, Craig AS, Schaffner W: Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis. 2007, 13 (7): 1024-1030. 10.3201/eid1307.070019.
Kelesidis T, Humphries R, Uslan DZ, Pegues DA: Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011, 52 (2): 228-234. 10.1093/cid/ciq113.
The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2334/14/514/prepub
This work was supported by the commissioned research grant from the Health and Medical Research Fund of the Food and Health Bureau, Hong Kong Special Administrative Region.
The authors declare that they have no competing interests.
VCCC and KYY designed, executed and supervised the study. VCCC, JWMT, and SCYW coordinated the infection control and collection of clinical specimens. JHKC and RWSP conducted quantitative culture and molecular characterization of VRE strains. VCCC drafted the manuscript. IFNH, KKWT, JFWC, PLH, CML and KYY critically reviewed the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Cheng, V.C., Chen, J.H., Tai, J.W. et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis 14, 514 (2014). https://0-doi-org.brum.beds.ac.uk/10.1186/1471-2334-14-514
- Vancomycin-resistant enterococci
- Bowel preparation
- Polyethylene glycol
- Lactobacillus rhamnosus GG